Jennifer L. Chain, Ph.D.
Dr. Jennifer Chain’s twenty-year career in scientific research has spanned academia, biotechnology industry, consulting, and non-profit. Beginning in 1998, Jennifer worked as research technician at the Oklahoma Medical Research Foundation (OMRF) and as undergraduate intern for the Howard Hughes Medical Institute in 1999.
She began her graduate work in 2000 at the University of Oklahoma Health Sciences Center studying human αβ and γδ thymocyte developmental checkpoints. In early 2006, Dr. Chain began her postdoctoral fellowships in Denver, Colorado; first at National Jewish Health where she studied γδ T cell activation and function, then at the University of Colorado Denver studying CD4 memory T cell senescence in clinical and autoimmune lung disorders.
In 2014 she followed her postdoctoral fellowships with an industry experience at a diagnostic testing company in Oklahoma called Moleculera Labs. There she studied biomarkers in autoimmune neuropsychiatric disorders. Common themes running through all of Dr. Chain’s early career research experiences were cellular and molecular immunology, new method development, and technical optimization. She designed and utilized advanced molecular biology, cell culture, flow cytometry, and other techniques to build the scientific tools needed for her projects.
To apply and expand on her diverse skill set, Dr. Chain started her own R&D consulting firm in 2016 called Experimental Solutions to help scientists advance their research and product development goals. As a consultant, she helped clients design, perform, and analyze experiments, train staff, manage projects, and write procedures, publications, grant applications, and marketing documents.
Dr. Chain now serves as the Science Officer for Cellular Therapies at the Oklahoma Blood Institute (OBI). Through the organization’s Bio-Development division, she is starting a stem cell and cell therapy research and development program, which is a continuation of the consulting work she provided OBI for over one year as a consultant before this appointment.
For more than 75 years, community-based blood centers have provided safe blood products to hospitals for the treatment of patients in need.
During this time, our specialized infrastructure, knowledge, and skill set has allowed us to successfully recruit and screen consenting donors; then to collect, test, characterize, store, distribute, and infuse our blood-based pharmaceutical products.
Bio-Sharing is a partnership between this community of blood centers. We are teaming up together to grow and expand our mission to collect and provide safe blood products for patient care by offering customized, reliable, and scalable cellular products for use in the research, development, and manufacture of your blood-based therapy.
When you visit Bio-Sharing.org, you will be able to request a whole host of products and services from this wide network of blood centers.
These products and services include, but are not limited to, purified T lymphocytes, dendritic cells, hematopoietic stem cells, mesenchymal stromal cells, serum, plasma, customized flow cytometry assays, HLA-typing, large-scale cGMP-compliant cell processing and expansion, and expertise in quality control and regulatory compliance.
You will also have access to a database of willing research participants, through Bio-Linked.org, with information about their personal and family medical and social history to help you find the right subjects for your research or clinical studies. There is also an option for customized questions that can be asked of the database members to further narrow down the right subjects.
Access to these products and services will help control the development and manufacturing costs of your new therapy and expand the base of research participants to the entire country.